We previously reported mother-to-child transmission of HIV-1 in 9 (6.7%) of 135 children on nevirapine prophylaxis in Vietnam. In the current study, we investigated the appearance and profile of anti-retroviral drug (ARV) resistance mutations, the predicted co-receptor usage, and the genetic diversity of HIV-1 strains isolated from the eight pairs of HIV-1-infected mothers and their children, who were followed up to 12 months after birth. Portions of the pol and env C2V3 regions of the HIV-1 strains were analyzed genetically. HIV-1 CRF01_AE RNA was detected in 4 (50%) children at delivery. Y181C, a nevirapine resistance mutation, appeared in 2 (25%) children 1 and 3 months after birth, respectively. No ARV resistance mutation was detected in the mothers, though three mothers were on ARV prophylaxis. Five mothers and their children harbored CCR5-tropic (R5) viruses. Two mothers harbored both R5 and CXCR4-tropic (X4) viruses, but their children harbored only R5 viruses even though the X4 viruses were dominant in the mothers. In the remaining one mother, HIV-1 RNA was not amplified and her child harbored both R5 and X4 viruses at birth, but only X4 virus 12 months after delivery. The infants' viruses were more homogenous than their mothers' (mean distance: 0.5% vs. 1.1%, respectively). This is the first molecular epidemiological study of vertical HIV-1 infections in Vietnam. These findings may provide useful knowledge for the prevention of mother-to-child transmission of HIV-1 and the anti-retroviral treatment of children in Vietnam. 
INTRODUCTION
Vertical transmission of human immunodeficiency virus type 1 (HIV-1) accounts for the vast majority of pediatric AIDS cases in the world. In 2012, more than 260,000 children less than 15 years of age were newly infected with HIV-1, more than 95% of these cases via motherto-child transmission (MTCT).
1,2 MTCT of HIV-1 can occur in utero, intra-partum, and postpartum through breast feeding. Perinatally acquired infections account for the majority of all HIV-1 cases in children, with an estimated MTCT rate of 14 to 48% without prevention. [3] [4] [5] [6] However, the timing and actual mechanisms of perinatal transmission are not clear.
The chemokine receptors CCR5 and CXCR4 are the main co-receptors for HIV-1 entry into target cells. 7 Based on chemokine co-receptor usage, HIV-1 can be classified as a CCR5-tropic (R5), CXCR4-tropic (X4), or dual tropic (R5X4) virus. 8 A strong selection for viral variants using CCR5 as a co-receptor occurs during transmission, as most children are infected with R5 viruses.
9-12
Prevention of mother-to-child transmission (PMTCT) of HIV-1 is one of the key components of the worldwide response to the pandemic and is based on the prophylactic use of anti-retroviral drugs (ARVs). In developed countries, MTCT of HIV-1 has been reduced to less than 2% by combination antiretroviral therapy (ART), selective caesarian delivery, and avoidance of breast feeding. 13, 14 In developing countries, single-dose nevirapine given to mothers infected with HIV-1 and their children in the intra-partum and immediate postnatal period is the most common intervention to reduce the MTCT of HIV-1. Single-dose nevirapine can reduce the risk of MTCT of HIV-1, 15 but it may lead to the emergence of nevirapine-resistant HIV-1 variants in children who are infected with HIV-1 despite the prophylaxis. 16 One study of HIV-1-infected Ugandan women and their children who received single-dose nevirapine to prevent MTCT showed nevirapine resistance mutations in 11 of 24 (46%) children by 6-8 weeks of age. In the present study, we investigated the appearance and profile of drug resistanceassociated mutations in infants under nevirapine prophylaxis, the predicted co-receptor usage, and the genetic diversity of HIV-1 strains in mothers and their infants in Hanoi and Haiphong, Northern Vietnam.
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METHODS
Study subjects
A total of 135 HIV-1-infected mothers and their children admitted to the Obstetrics and Gynecology hospitals in Hanoi and Haiphong, Northern Vietnam, were enrolled in our previous study. 22 Blood samples were collected from the mothers on the day of delivery and from their infants within 1-2 days after birth between 2004 and 2006. Blood samples were also collected from the infants 1, 3, 6, and/or 12 months after birth, although some motherand-child pairs, especially who lived far from the hospital, could not come to the hospital at all the sample collection times. Plasma was separated from the blood samples within 8 hours of collection and stored at -80° C until analysis.
For the current study 38 mother-and-child pairs including one with a child vertically infected with HIV-1 were excluded for the lack of their mothers' plasma samples.
Plasma samples from the remaining 97 pairs were still available and transferred to Kanazawa University for further analyses ( Figure 1 ). Of the 97 children samples eight were confirmed to be positive for HIV-1 RNA (Table 1) . Of the eight HIV-1-infected children, one (HP25) was born to a mother given zidovudine/lamivudine/nelfinavir 1 to 3 weeks before delivery, two (HN51and HN88) were born to mothers given single-dose nevirapine at delivery, and five (HN23, HN46, HN 47, HN60, and HP13) were born to mothers without any prophylaxis.
After birth, all children were given single-dose nevirapine (2 mg of liquid nevirapine/kg body weight) within 48 hours of delivery and fed formula, and one child (HP25) whose mother received combination ART before delivery was given liquid zidovudine for 7 days after birth according to the Vietnamese national guidelines. 20 All of the plasma samples collected from the eight HIV-1-infected children within 1-2 days after birth were available, but only a part of the samples collected from these children 1, 3, 6 and/or 12 months after birth were available 6 as shown in with one cycle at 95°C for 10 min, followed by 40 cycles at 95°C for 30 sec, 55°C for 30 sec, and 72°C for 1 min, with a final extension at 72°C for 10 min using Ampli Taq Gold. Nested 7 PCR for pol-RT was performed with one cycle at 94°C for 1 min and 35 cycles at 98°C for 10 sec, 55°C for 30 sec (for DRRT7L/DRRT6L primer set) or 45°C for 30 sec (for KT101/K102 primer set), and 68°C for 5 min using KOD FX.
23-25
The HIV-1 env C2V3 region (366 bases) was amplified using the primers JA167mod/JA170mod in the first round and JA168mod/JA169mod in the second round.
Amplification was performed with one cycle of 95°C for 2 min and 40 cycles of 95°C for 30 sec, 55°C for 30 sec, and 68°C for 1 min, with a final extension of 72°C for 10 min.
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The amplified products were detected by staining the gel with ethidium bromide after electrophoresis. The amplified products of the PR and RT regions were sequenced directly with BigDye Terminator v1.1 on an ABI PRISM 310 Genetic Analyzer (Applied Biosystems).
The amplified products of the env C2V3 region were cloned using the TOPO TA kit (Invitrogen) as described previously. 27 Eleven to 42 clones were sequenced for each sample using BigDye Terminator v1.1 on a 3500XL sequencer (Applied Biosystems).
Drug resistance
HIV-1 pol PR and RT sequences were analyzed for drug resistance mutations using the 
Co-receptor usage
HIV co-receptor usage was predicted based on the net charge of amino acids in the env V3 region, which was calculated by subtracting the number of acidic amino acids [aspartate (D) 8 and glutamate (E)] from the number of basic amino acids [lysine (K) and arginine (R)]. A net charge less than +5 in the V3 region has been shown to predict CCR5 usage (R5 virus), whereas a net charge of more than +5 has been shown to predict CXCR4 usage (X4 virus), and a net charge equal to +5 indicates R5 variants unless accompanied by an arginine or lysine residue at position 11 or 25 of the V3 amino acid sequences.
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Phylogenetic analysis
A phylogenetic tree was constructed based on the HIV-1 env C2V3 region to elucidate the genetic variations between the mothers' and their children's viruses using ClustalW (version 1.83) with the neighbor-joining method, and its reliability was estimated by 1,000 bootstrap replications. The distance of the env C2V3 region at each time point in each subject and between mother and infant pairs was analyzed by Mega5.
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RESULTS
HIV-1 vertical transmission and drug resistance mutations
Of the eight HIV-1-infected children, four were positive for HIV-1 RNA at birth, and the remaining four were negative at birth and became positive for HIV-1 RNA 1 (HN47 and HN60), 3 (HN88), or 6 (HN23) months after birth (Figures 1 and 2 , Tables 1 and 2 ). All HIV-1 strains detected in the mothers and their infants were CRF01_AE (data not shown),
although HIV-1 RNA was not amplified in the sample from one mother (HN46). In the HIV-1 strains detected in the mothers, no reverse transcriptase inhibitor (RTI) or protease inhibitor (PI) resistance mutations were found. No ARV resistance mutations were detected in the children at birth, but Y181C, a non-nucleoside reverse transcriptase inhibitor (NNRTI) resistance mutation, appeared in two (25%) children 1 (HN51) and 3 (HP25) months after birth, respectively. No NRTI or PI resistance mutations were found in these children during the follow-up period (Table 1) .
Genetic diversity of HIV-1 in the mother-children pairs
Clonal sequencing of the HIV-1 env C2V3 region was performed, and the genetic distance of the clones within each subject was calculated ( Table 1 ). The mean genetic distance of the nucleotide sequences in the mothers ranged from 0.00 to 2.82% (median value: 1.09%) and from 0.06 to 2.05% (median value: 0.50%) in the children. In five pairs, the children's sequences had less diversity than their mother's sequences. In two pairs, the children's sequences had higher diversity than their mother's sequences (0.17% at birth and 0.14% 1 month after birth vs. 0.07% in HN51, and 0.52% vs. 0.00% in HN60). Thus, the children's sequences were generally more homogeneous than their mothers' sequences.
In the child HP25, the viral genetic diversity increased from 0.06% at birth to 0.89% 3 months after birth, whereas in the child HN51 it decreased slightly from 0.17% at birth to 0.14% 1 month after birth.
Predicted HIV-1 co-receptor usage
The multiple alignments of the amino acid sequences of the HIV-1 env V3 region and the predicted co-receptor usage of HIV-1 strains isolated from the eight mother-and-child pairs are shown in Table 2 . Five mothers and their children (HN23, HN47, HN51, HN60, and HN88) harbored R5 viruses. Two mothers (HP13 and HP25) harbored both R5 and X4
viruses, whereas their children harbored only R5 viruses. In the remaining one mother (HN46), HIV-1 RNA could not be amplified and her child harbored both R5 and X4 viruses at birth, but only X4 virus 12 months after delivery.
Phylogenetic analysis of HIV-1 env C2V3 regions
To examine the viral genetic relationship between each mother and her child, we performed phylogenetic analyses based on the HIV-1 env C2V3 nucleotide sequences (Figure 2) . In five mother-child pairs (HN23, HN47, HN88, HP13, and HP25), the HIV-1 strains of the children formed more homogeneous clusters than the strains of the mothers (Figure 2A , C, and F-H), whereas in the HN51 and HN60 pairs the mothers' viruses formed more homogeneous clusters than the children's viruses ( Figure 2D and E). In the HP25 child, the viral population was very homogenous at birth, but its diversity spread significantly 3 months after birth ( Figure 2H ). In the HN51 pair, the child's viruses formed two independent clusters, at birth and 1 month after birth. Interestingly, the child's virus population 1 month after birth was much closer to the mother's virus population than the child's virus population at birth ( Figure   2D ). In the HP13 and HP25 pairs, the mothers' virus populations consisted of both R5 and 11 X4 viruses, whereas their children's consisted of only R5 viruses, even though X4 viruses were dominant in their mothers ( Figure 2G and H). In the remaining pair, HN46, in which maternal HIV-1 RNA was not amplified, the child's viruses exhibited high diversity at birth as well as 12 months after birth, and the virus population at birth consisted of both R5 and X4 viruses ( Figure 2B) .
DISCUSSION
In the current study, we investigated the appearance and profile of ARV-resistance mutations, the predicted co-receptor usage, and the genetic diversity of the HIV-1 strains isolated from eight pairs of HIV-1-infected mothers and their children in Northern Vietnam. All of the children were given single-dose nevirapine at birth and followed for up to 12 months. This is the first molecular epidemiological study of vertical HIV-1 infection in Vietnam.
Of the eight HIV-1-infected children, four were positive for HIV-1 RNA at birth, suggesting in utero transmission of HIV-1, and four children became positive 1, 3, and 6 months after birth, suggesting intra-partum transmission of HIV-1. All of the children were fed formula. Therefore, most of the children who failed PMTCT of HIV-1, even with singledose nevirapine within 48 hours after birth, might be infected with HIV-1 in utero and intrapartum.
The HIV-1 strains harboring a major nevirapine resistance mutation, Y181C, appeared in 2 (25%) of the 8 children 1 and 3 months after birth. This finding is consistent with a previous study in Ethiopia that reported a prevalence of 26% for the drug resistance mutation in children who received single-dose nevirapine from 2001 to 2007, and that Y181C
was the most dominant mutation in the children. 32 Other studies have reported nevirapine resistance mutations among 33-38% of HIV-infected children when both the children and their mothers were exposed to single-dose nevirapine. [33] [34] [35] [36] In the current study, the nevirapine resistance mutation was not detected in the children at birth, and no ARV resistance mutations were detected in their mothers, suggesting that the drug resistance mutation developed in the children independently after nevirapine administration. These findings completely agree with previous reports that most resistance mutations to nevirapine in children are selected de novo when the virus is exposed to nevirapine rather than being transmitted from their mothers. In the present study, two children (HP13 and HP25) born to mothers who had both R5
and X4 viruses harbored only R5 viruses at birth, despite the X4 viruses being dominant in the mothers, demonstrating selected transmission of R5 virus from mother to child. These findings are consistent with previous studies in which the R5 phenotype was predominantly transmitted from mother to child. 38,39 In contrast, one child (HN46) harbored both R5 and X4
viruses at birth with relatively high diversity, suggesting that multiple HIV-1 strain transmission occurred in utero and evolved to some extent by delivery. However, whether HIV infection was initiated with both R5 and X4 viruses or only R5 virus(es) that evolved in utero to produce X4 virus populations in this child cannot be determined because no data was available on the mother's virus and X4 and R5/X4 viruses can be transmitted from mother to child before, during, or shortly after delivery.
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In the current study, we found that the viral populations of the children were more homogeneous than those of their mothers at delivery, suggesting "bottle-neck transmission"
of HIV-1 variants from mother to child. 31 However, in the two mother-child pairs, the children's viral populations at birth and 1 month (HN51) and 3 months (HN60) after birth exhibited higher genetic diversity than their mothers', suggesting recent infection of the mothers with HIV-1 and rapid viral replication and evolution in these children after birth.
14 This is in agreement with a study from Sweden in which the children's viral populations were more heterogeneous than the mothers' viral populations. n/a n/a n/a n/a C-1 n/a n/a n/a n/a C-3 n/a n/a n/a n/a C-6 n/a n/a Fail R5 0.11 (0.09) 0.00 (0.00) HN46 M n/a n/a n/a n/a C-0 n/a n/a n/a n/a C-1 None None None n/a n/a n/a n/a C- n/a n/a n/a n/a C- M, mother; C, children; C-0, at delivery; C-1, 1 month; C-3, 3 months; C-6, 6 months; C-12, 12 months after birth; NRTI, nucleoside reverse transcriptase inhibitors; NNRTI, non-nucleoside reverse transcriptase inhibitors; PI, protease inhibitor; None, no resistance mutation was detected. Italics, minor mutations; Bold, major mutation; R5, CCR5; X4, CXCR4; Fail, PCR (+) but population sequencing was not successful; n/a, no PCR amplification. Distance is expressed as the percent nucleotides or amino acid. Table 2 . V3 amino acid sequence alignment and predicted co-receptor usage of HIV-1 strains isolated from mothers and their children in Northern Vietnam
